CYTO Altamira Therapeutics Ltd.
Healthcare$0.30+0.00%ClosedMarket Cap: $1.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.02
P/S
0.00
EV/EBITDA
-0.37
DCF Value
—
FCF Yield
-548.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-111.6%
ROA
-84.0%
ROIC
-77.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY null | $0.00 | NaN% | $-5.9M | $-7.3M | $— | — |
| Q2 null | $52.7K | -101.2% | $-2.3M | $-2.7M | $— | — |
| Q1 null | $52.7K | -101.2% | $-2.3M | $-2.7M | $— | — |
| Q4 null | $0.00 | NaN% | $5.9M | $-802.0K | $— | — |
| FY null | $305.6K | -372.4% | $-18.0M | $-26.5M | $— | — |
| Q3 null | $-459.0K | 127.5% | $-3.1M | $-9.6M | $— | — |
| Q2 null | $145.4K | -310.2% | $-4.2M | $-4.1M | $— | — |
| Q1 null | $145.4K | -310.2% | $-4.2M | $-4.1M | $— | — |
| Q4 null | $0.00 | NaN% | $5.5M | $5.2M | $— | — |
| FY null | $63.9K | -3407.3% | $-5.3M | $-17.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.4M | $-5.2M | $— | — |
| Q2 2021 | $0.00 | NaN% | $-3.2M | $-3.4M | $-108.47 | — |